Mergers & acquisitions
Semma will become a separate operating subsidiary of Vertex. Semma is working to advance Melton’s methodology for creating billions of functional, insulin-producing beta cells.
“This transaction advances Zogenix’s mission to become a leading rare disease pharmaceutical company by adding MT1621 to our pipeline of late-stage Fintepla programs,” stated Stephen J. Farr, president and chief executive officer of Zogenix.
Singapore molecular diagnostics groups INEX Innovations Exchange Pte. Ltd. (INEX) and Nova Satra Dx Pte. Ltd. (Nova Satra) announced the merger of the two companies to create INEX INNOVATE.
Addition of ImmunArray autoimmune testing assets, Nudge patient-engagement capabilities enhances diagnostic and patient support offerings
LGC announced the acquisition of a majority stake in Toronto Research Chemicals, a leading manufacturer and supplier of synthetic organic bio-chemicals which are used as reference standards, research tools and building blocks by a highly diversified global customer base across the pharmaceutical, applied and research sectors.
Cambrex Corporation announced that it has signed a definitive agreement to be acquired by an affiliate of the Permira funds in a transaction valued at approximately $2.4 billion, including Cambrex’s net debt.
Under the terms of the acquisition, Bayer is buying the rest of the company for $240 million up front with an additional $360 million in various development milestones. This will correspond with the company’s value of about $1 billion.
Gene therapy companies could be continued M&A targets for larger ones as more and more companies are looking to broaden their therapeutic focus with potential one-time therapies for various diseases.
Permira initiated the transaction after Cambrex flexed its own M&A muscle and acquired Avista and Halo.
The owners of Cytena GmbH have agreed to sell all Cytena shares to CELLINK AB for a purchase price of 30.25M euros.
PRESS RELEASES